Status:
COMPLETED
Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Falciparum Malaria
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Malaria, endemic in 85 countries, remains a major concern. By 2022, there will be 249 million cases and 608,000 deaths, 94% of them in Africa. In France, 4995 cases of imported malaria were reported i...
Eligibility Criteria
Inclusion
- Male or female over 18 years of age
- Have been diagnosed with severe malaria according to WHO criteria and have been treated between 1/1/2018 and 321/12/2024 at the AP-HM
- Have been treated with Artesunate IV (MALACEF®) (at least one dose)
- Patient who has received information about the study and has not expressed opposition
- Patient benefiting or entitled to benefit from a social security scheme
Exclusion
- Patients with advanced neurodegenerative pathology pre-existing the malaria attack
- Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women),
- Persons who do not understand French
Key Trial Info
Start Date :
June 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06992297
Start Date
June 17 2025
End Date
September 13 2025
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hopitaux de Marseille
Marseille, France, 13354